Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Feb 10, 2021

(R) Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa extension cohort

Dec 30, 2020

(R) New number of shares and votes in Cantargia

Dec 21, 2020

(R) Changes to Cantargia’s nomination committee

Dec 16, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 564 million

Dec 15, 2020

(R) Cantargia announces intention of a directed share issue

Nov 26, 2020

BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

Nov 12, 2020

(R) Cantargia publishes interim report for third quarter 2020

Oct 20, 2020

(R) Nomination Committee appointed ahead of 2021 Annual General Meeting

Oct 13, 2020

(R) Extraordinary general meeting in Cantargia AB (publ)

Oct 8, 2020

(R) Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye